Cogent Biosciences (COGT) Current Deferred Revenue (2017 - 2020)

Cogent Biosciences (COGT) has 4 years of Current Deferred Revenue data on file, last reported at $312000.0 in Q2 2020.

• On a quarterly basis, Current Deferred Revenue fell 97.95% year-over-year to $312000.0 in Q2 2020; TTM through Jun 2020 was $312000.0, a 97.95% decrease from a year earlier, with the FY2019 full-year figure at $1.3 million, down 92.67% from the prior year.
• Current Deferred Revenue for Q2 2020 stood at $312000.0, down from $841000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for COGT reached as high as $20.4 million in Q2 2018 and fell as low as $312000.0 in Q2 2020.
• Historically, Current Deferred Revenue has averaged $12.0 million across 4 years, with a median of $15.2 million in 2019.
• Across the five-year window, Current Deferred Revenue jumped 160.47% in 2018 and plunged 97.95% in 2020, its largest moves.
• Year by year, Current Deferred Revenue stood at $6.9 million in 2017, then soared by 160.47% to $17.9 million in 2018, then sank by 92.67% to $1.3 million in 2019, then sank by 76.27% to $312000.0 in 2020.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $312000.0 in Q2 2020, $841000.0 in Q1 2020, and $1.3 million in Q4 2019.